Skip to main content
BioInvent International logo

BioInvent International — Investor Relations & Filings

Ticker · BINV ISIN · SE0015244520 LEI · 549300E7QRHEF2IJUY10 ST Manufacturing
Open in API
Filings indexed 679 across all filing types
Latest filing 2022-06-16 Board/Management Inform…
Country SE Sweden
Listing ST BINV

About BioInvent International

https://www.bioinvent.com/en

BioInvent International is a clinical-stage company that discovers and develops novel, first-in-class immuno-modulatory antibodies for cancer therapy. Leveraging extensive expertise in immunology, cancer biology, and antibody biology, the company generates innovative immuno-oncology drug candidates for its clinical pipeline. BioInvent's operations include an in-house manufacturing facility to produce antibodies for its preclinical studies and clinical trials, with the goal of developing treatments that can transform the lives of cancer patients.

Recent filings

Filing Released Lang Actions
Natalie Berner of Redmile and Nanna Lüneborg of Forbion proposed as new Board members of BioInvent
Board/Management Information Classification · 95% confidence The document is a press release announcing the nomination of two new candidates for the Board of Directors of BioInvent, to be voted upon at an upcoming Extraordinary General Meeting (EGM). Since the document focuses on the announcement of changes to the board composition, it falls under the 'Board/Management Information' category.
2022-06-16 English
Exelixis and BioInvent Establish Exclusive Option and License Agreement to Develop Novel Antibody-Based Immuno-Oncology Therapies
Regulatory Filings Classification · 99% confidence The document is a press release dated June 16, 2022, announcing an exclusive option and license agreement between Exelixis, Inc. and BioInvent International AB regarding the development of novel antibody-based immuno-oncology therapies. It details financial terms (\$25 million upfront fee), collaboration structure, and future milestones. This type of announcement, detailing a significant business development, partnership, or financing arrangement, fits best under the 'Capital/Financing Update' category, as it involves a substantial upfront payment and future financial obligations related to drug development rights. While it is a business development announcement, 'CAP' covers fundraising, financing activities, or capital structure changes, which this agreement fundamentally is (acquiring rights/assets for a fee). It is not a standard regulatory filing (10-K, ER, IR), nor is it a management change (MANG) or a dividend notice (DIV). Given the focus on the financial transaction and licensing rights acquisition, CAP is the most appropriate fit among the provided options, although 'RNS' (Regulatory Filings) could also apply if CAP were deemed too narrow. However, the core of the news is the capital exchange for development rights, leaning towards CAP.
2022-06-16 English
Exelixis och BioInvent sluter exklusivt options- och licensavtal för utveckling av nya, antikroppsbaserade immunonkologiska behandlingar
Regulatory Filings Classification · 100% confidence The document is a press release, dated June 16, 2022, announcing an exclusive option and license agreement between Exelixis, Inc. and BioInvent International AB regarding the development of new antibody-based immuno-oncology treatments. It details upfront payments, milestone payments, and royalty structures related to this collaboration. This type of announcement, detailing a significant business development, financing arrangement, or partnership, fits best under the 'Capital/Financing Update' (CAP) category if it involves significant financial terms, or potentially 'Regulatory Filings' (RNS) if it's a general disclosure required by market rules. Since the core of the document is the financial and strategic terms of a licensing deal, which often involves capital structure implications or significant future financial commitments, 'CAP' is a strong candidate. However, given the context of a press release announcing a major business deal (licensing/collaboration) that is not strictly fundraising or capital structure change, and the presence of the final line stating the information is subject to EU Market Abuse Regulation disclosure requirements, it is a general regulatory announcement. Since 'M&A Activity' (TAR) is for takeovers/mergers, and this is a licensing deal, the most appropriate general regulatory disclosure category is 'RNS' (Regulatory Filings) as it is a broad announcement of material information not covered by more specific codes like DIV, ER, or 10-K. The document is a full announcement, not just a notice that a report is attached, so RPA is not the primary fit.
2022-06-16 Swedish
Major Shareholding Notification 2022
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding percentage for a specific holder ('Forbion Growth Opportunties Fund I Cooperatief U.A.') in the issuer ('BioInvent International Aktiebolag'). It explicitly shows the 'Before the transaction' and 'After the transaction' share counts and resulting percentages, crossing a threshold (5%). This type of filing, reporting changes in significant share ownership, directly corresponds to the Major Shareholding Notification category.
2022-06-08 English
Beslut på BioInvents årsstämma 2022
AGM Information Classification · 99% confidence The document is titled "Beslut på BioInvents årsstämma 2022" (Decisions at BioInvent's Annual General Meeting 2022). The text explicitly details the resolutions passed at the Annual General Meeting (Årsstämma), including the re-election of board members, approval of financial statements, decisions on remuneration, and approval of an incentive program. This content directly corresponds to the materials presented or decided upon during an AGM. Therefore, the classification is AGM-R (AGM Information). The document is the official summary of the decisions, not just an announcement of a future meeting or a proxy statement.
2022-04-28 Swedish
Resolutions at BioInvent’s Annual General Meeting 2022
AGM Information Classification · 100% confidence The document is explicitly titled "Resolutions at BioInvent's Annual General Meeting 2022". It details the outcomes of voting on various matters, including the re-election of board members, approval of financial statements for 2021, decisions on remuneration, and the implementation of an incentive program. These are the core components of an Annual General Meeting (AGM) resolution summary. Therefore, the correct classification is AGM-R (AGM Information). The document length (6232 chars) is substantial enough to be the primary document, not just an announcement of one.
2022-04-28 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.